Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 3.9 Million AUD | -78.44% |
| 2023 | 18.11 Million AUD | 295.64% |
| 2022 | 3.1 Million AUD | -55.59% |
| 2021 | 7 Million AUD | 16.06% |
| 2020 | 6.03 Million AUD | 2.07% |
| 2019 | 5.91 Million AUD | 0.75% |
| 2018 | 5.86 Million AUD | -26.87% |
| 2017 | 8.02 Million AUD | -7.2% |
| 2016 | 8.64 Million AUD | -20.52% |
| 2015 | 10.87 Million AUD | -13.54% |
| 2014 | 12.57 Million AUD | 18.94% |
| 2013 | 10.57 Million AUD | -30.82% |
| 2012 | 15.28 Million AUD | 0.63% |
| 2011 | 15.19 Million AUD | 3.2% |
| 2010 | 14.72 Million AUD | -27.06% |
| 2009 | 20.18 Million AUD | 20.2% |
| 2008 | 16.79 Million AUD | 91.9% |
| 2007 | 8.74 Million AUD | 9.37% |
| 2006 | 8 Million AUD | -36.61% |
| 2005 | 12.62 Million AUD | 52.98% |
| 2004 | 8.25 Million AUD | -39.29% |
| 2003 | 13.58 Million AUD | -38.19% |
| 2002 | 21.98 Million AUD | 142.56% |
| 2001 | 9.06 Million AUD | 32.83% |
| 2000 | 6.82 Million AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.8 Million AUD | 43.08% |
| 2024 FY | 8.27 Million AUD | -32.76% |
| 2024 Q2 | 3.18 Million AUD | 0.0% |
| 2024 Q3 | 3.13 Million AUD | -1.55% |
| 2024 Q4 | 3.13 Million AUD | 0.0% |
| 2023 FY | 12.3 Million AUD | 295.64% |
| 2023 Q1 | 4.25 Million AUD | -41.28% |
| 2023 Q3 | 4.8 Million AUD | 24.97% |
| 2023 Q4 | 3.35 Million AUD | -30.09% |
| 2023 Q2 | 3.84 Million AUD | -9.55% |
| 2022 Q3 | 3.58 Million AUD | -37.25% |
| 2022 Q2 | 5.71 Million AUD | 83.78% |
| 2022 Q4 | 7.23 Million AUD | 101.91% |
| 2022 FY | 3.1 Million AUD | -55.59% |
| 2022 Q1 | 3.1 Million AUD | -18.48% |
| 2021 Q2 | 4.17 Million AUD | 152.94% |
| 2021 Q1 | 1.65 Million AUD | -57.94% |
| 2021 FY | 7 Million AUD | 16.06% |
| 2021 Q4 | 3.81 Million USD | 52.97% |
| 2021 Q3 | 2.49 Million AUD | -40.28% |
| 2020 Q4 | 3.92 Million AUD | 119.4% |
| 2020 FY | 6.03 Million AUD | 2.07% |
| 2020 Q2 | 2.88 Million AUD | 135.61% |
| 2020 Q3 | 1.78 Million AUD | -37.95% |
| 2020 Q1 | 1.22 Million AUD | -60.74% |
| 2019 Q1 | 1.52 Million AUD | 46.36% |
| 2019 FY | 5.91 Million AUD | 0.75% |
| 2019 Q2 | 1.52 Million AUD | 0.0% |
| 2019 Q3 | 1.56 Million AUD | 2.53% |
| 2019 Q4 | 3.11 Million USD | 99.17% |
| 2018 Q4 | 1.04 Million AUD | 0.0% |
| 2018 FY | 5.86 Million AUD | -26.87% |
| 2018 Q2 | 1.62 Million AUD | 0.0% |
| 2018 Q1 | 1.62 Million AUD | -23.71% |
| 2018 Q3 | 1.04 Million AUD | -35.93% |
| 2017 Q4 | 2.13 Million AUD | 0.0% |
| 2017 Q3 | 2.13 Million AUD | 2.27% |
| 2017 Q2 | 2.08 Million AUD | -0.0% |
| 2017 Q1 | 2.08 Million AUD | -0.18% |
| 2017 FY | 8.02 Million AUD | -7.2% |
| 2016 Q4 | 2.08 Million AUD | 0.0% |
| 2016 Q2 | 2.2 Million AUD | -0.0% |
| 2016 Q1 | 2.2 Million AUD | 0.63% |
| 2016 Q3 | 2.08 Million AUD | -5.03% |
| 2016 FY | 8.64 Million AUD | -20.52% |
| 2015 FY | 10.87 Million AUD | -13.54% |
| 2015 Q4 | 2.18 Million AUD | 0.0% |
| 2015 Q3 | 2.18 Million AUD | -10.73% |
| 2015 Q2 | 2.44 Million AUD | 0.0% |
| 2015 Q1 | 2.44 Million AUD | -19.76% |
| 2014 Q4 | 3.05 Million AUD | 0.0% |
| 2014 FY | 12.57 Million AUD | 18.94% |
| 2014 Q2 | 2.52 Million AUD | -0.0% |
| 2014 Q1 | 2.52 Million AUD | -7.78% |
| 2014 Q3 | 3.05 Million AUD | 20.89% |
| 2013 Q1 | 1.54 Million AUD | 0.0% |
| 2013 FY | 10.57 Million AUD | -30.82% |
| 2013 Q3 | 2.73 Million AUD | 77.52% |
| 2013 Q2 | 1.54 Million AUD | 0.0% |
| 2013 Q4 | 2.73 Million AUD | 0.0% |
| 2012 FY | 15.28 Million AUD | 0.63% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | 15.19 Million AUD | 3.2% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | 14.72 Million AUD | -27.06% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | 20.18 Million AUD | 20.2% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | 16.79 Million AUD | 91.9% |
| 2008 Q1 | - AUD | -100.0% |
| 2008 Q2 | 3.71 Million AUD | 0.0% |
| 2008 Q4 | -17.68 Million AUD | 0.0% |
| 2008 Q3 | - AUD | -100.0% |
| 2007 Q3 | - AUD | -100.0% |
| 2007 Q4 | 5.05 Million AUD | 0.0% |
| 2007 FY | 8.74 Million AUD | 9.37% |
| 2007 Q2 | 3.68 Million AUD | 0.0% |
| 2007 Q1 | - AUD | -100.0% |
| 2006 Q3 | - AUD | -100.0% |
| 2006 Q4 | 5.34 Million AUD | 0.0% |
| 2006 Q1 | - AUD | 100.0% |
| 2006 FY | 8 Million AUD | -36.61% |
| 2006 Q2 | 4.28 Million AUD | 0.0% |
| 2005 FY | 12.62 Million AUD | 52.98% |
| 2005 Q4 | -17.23 Million AUD | 0.0% |
| 2005 Q1 | - AUD | 0.0% |
| 2005 Q2 | 2.46 Million AUD | 0.0% |
| 2005 Q3 | - AUD | -100.0% |
| 2004 FY | 8.25 Million AUD | -39.29% |
| 2003 FY | 13.58 Million AUD | -38.19% |
| 2002 FY | 21.98 Million AUD | 142.56% |
| 2001 FY | 9.06 Million AUD | 32.83% |
| 2000 FY | 6.82 Million AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 97.379% |
| Prenetics Global Limited | 60.73 Million USD | 93.571% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 76.005% |
| CareDx, Inc | 277.76 Million USD | 98.594% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.811% |
| Exagen Inc. | 52.29 Million USD | 92.533% |
| Inotiv, Inc. | 246.9 Million USD | 98.419% |
| Guardant Health, Inc. | 901.62 Million USD | 99.567% |
| Biodesix, Inc. | 77.41 Million USD | 94.957% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | 0.474% |
| Precipio, Inc. | 13.63 Million USD | 71.371% |
| iSpecimen Inc. | 16.27 Million USD | 76.013% |
| Natera, Inc. | 938.98 Million USD | 99.584% |
| Aspira Women's Health Inc. | 24.11 Million USD | 83.808% |
| Standard BioTools Inc. | 113.48 Million USD | 96.56% |
| 23andMe Holding Co. | 420.73 Million USD | 99.072% |
| Castle Biosciences, Inc. | 242.78 Million USD | 98.392% |
| Personalis, Inc. | 128.14 Million USD | 96.953% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 96.467% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | 76.317% |
| OpGen, Inc. | 30.65 Million USD | 87.264% |
| T2 Biosystems, Inc. | 41.49 Million USD | 90.59% |
| Myriad Genetics, Inc. | 600.1 Million USD | 99.349% |
| ICON Public Limited Company | 755.64 Million USD | 99.483% |
| NeoGenomics, Inc. | 341.25 Million USD | 98.856% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 76.005% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 99.643% |
| RadNet, Inc. | 268.87 Million USD | 98.548% |
| MDxHealth SA | 71.25 Million USD | 94.52% |
| Psychemedics Corporation | 11.33 Million USD | 65.551% |
| Illumina, Inc. | 3.81 Billion USD | 99.898% |
| Check-Cap Ltd. | 19.28 Million USD | 79.756% |
| Twist Bioscience Corporation | 354.18 Million USD | 98.898% |
| DarioHealth Corp. | 62.17 Million USD | 93.72% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 97.729% |
| Sera Prognostics, Inc. | 39.91 Million USD | 90.219% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | 62.888% |
| OPKO Health, Inc. | 574.68 Million USD | 99.321% |
| Medpace Holdings, Inc. | 187.68 Million USD | 97.92% |
| Neogen Corporation | 405.23 Million USD | 99.036% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | 66.654% |
| Prenetics Global Limited | 60.73 Million USD | 93.571% |
| Mainz Biomed B.V. | 27.15 Million USD | 85.621% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | 55.453% |
| Trinity Biotech plc | 46.49 Million USD | 91.602% |
| Neuronetics, Inc. | 82.25 Million USD | 95.253% |
| Sotera Health Company | 300.46 Million USD | 98.701% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | 55.453% |